Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

BHC vs PRGO vs PBH vs TEVA vs CVS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
BHC
Bausch Health Companies Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • CA
Market Cap$2.14B
5Y Perf.-69.0%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-78.6%
PBH
Prestige Consumer Healthcare Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$2.58B
5Y Perf.+29.4%
TEVA
Teva Pharmaceutical Industries Limited

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IL
Market Cap$41.93B
5Y Perf.+187.4%
CVS
CVS Health Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$111.40B
5Y Perf.+33.2%

BHC vs PRGO vs PBH vs TEVA vs CVS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
BHC logoBHC
PRGO logoPRGO
PBH logoPBH
TEVA logoTEVA
CVS logoCVS
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericMedical - DistributionDrug Manufacturers - Specialty & GenericMedical - Healthcare Plans
Market Cap$2.14B$1.61B$2.58B$41.93B$111.40B
Revenue (TTM)$10.55B$4.18B$1.10B$17.35B$407.90B
Net Income (TTM)$-1.19B$-1.82B$187M$1.56B$2.93B
Gross Margin61.7%34.2%56.4%52.1%13.9%
Operating Margin22.9%-4.1%29.2%13.2%1.5%
Forward P/E1.3x5.6x12.0x14.5x12.2x
Total Debt$21.21B$3.97B$1.04B$17.38B$93.59B
Cash & Equiv.$1.32B$532M$98M$3.56B$8.51B

BHC vs PRGO vs PBH vs TEVA vs CVSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

BHC
PRGO
PBH
TEVA
CVS
StockMay 20May 26Return
Bausch Health Compa… (BHC)10031.0-69.0%
Perrigo Company plc (PRGO)10021.4-78.6%
Prestige Consumer H… (PBH)100129.4+29.4%
Teva Pharmaceutical… (TEVA)100287.4+187.4%
CVS Health Corporat… (CVS)100133.2+33.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: BHC vs PRGO vs PBH vs TEVA vs CVS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BHC and PBH are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Prestige Consumer Healthcare Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. PRGO, TEVA, and CVS also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
BHC
Bausch Health Companies Inc.
The Growth Play

BHC has the current edge in this matchup, primarily because of its strength in growth exposure.

  • Rev growth 8.5%, EPS growth 430.8%, 3Y rev CAGR 8.7%
  • 8.5% revenue growth vs PRGO's -2.8%
  • Lower P/E (1.3x vs 12.2x)
Best for: growth exposure
PRGO
Perrigo Company plc
The Income Pick

PRGO ranks third and is worth considering specifically for income & stability and defensive.

  • Dividend streak 10 yrs, beta 1.18, yield 9.8%
  • Beta 1.18, yield 9.8%, current ratio 2.76x
  • 9.8% yield, 10-year raise streak, vs CVS's 3.1%, (3 stocks pay no dividend)
Best for: income & stability and defensive
PBH
Prestige Consumer Healthcare Inc.
The Defensive Pick

PBH is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.

  • Lower volatility, beta 0.53, Low D/E 56.9%, current ratio 4.20x
  • 16.9% margin vs PRGO's -43.5%
  • 5.3% ROA vs PRGO's -19.8%, ROIC 9.1% vs 3.7%
Best for: sleep-well-at-night
TEVA
Teva Pharmaceutical Industries Limited
The Momentum Pick

TEVA is the clearest fit if your priority is momentum.

  • +104.6% vs PRGO's -51.2%
Best for: momentum
CVS
CVS Health Corporation
The Insurance Pick

CVS is the clearest fit if your priority is long-term compounding.

  • 3.5% 10Y total return vs PBH's -3.7%
  • Beta 0.05 vs PRGO's 1.18, lower leverage
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthBHC logoBHC8.5% revenue growth vs PRGO's -2.8%
ValueBHC logoBHCLower P/E (1.3x vs 12.2x)
Quality / MarginsPBH logoPBH16.9% margin vs PRGO's -43.5%
Stability / SafetyCVS logoCVSBeta 0.05 vs PRGO's 1.18, lower leverage
DividendsPRGO logoPRGO9.8% yield, 10-year raise streak, vs CVS's 3.1%, (3 stocks pay no dividend)
Momentum (1Y)TEVA logoTEVA+104.6% vs PRGO's -51.2%
Efficiency (ROA)PBH logoPBH5.3% ROA vs PRGO's -19.8%, ROIC 9.1% vs 3.7%

BHC vs PRGO vs PBH vs TEVA vs CVS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

BHCBausch Health Companies Inc.
FY 2025
Product
49.5%$10.2B
Pharmaceutical Products
23.1%$4.7B
Device Products
11.9%$2.4B
Over the Counter Products
9.8%$2.0B
Branded and Other Generic Products
4.7%$962M
Other Revenues
0.5%$110M
Product and Service, Other
0.5%$110M
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
PBHPrestige Consumer Healthcare Inc.
FY 2025
Gastrointestinal
22.5%$256M
Women's Health
20.8%$237M
Eye and Ear Care
16.1%$183M
Dermatologicals
11.3%$129M
Analgesics
10.3%$118M
Cough and Cold
9.3%$106M
Oral Care
8.4%$95M
Other (1)
1.2%$14M
TEVATeva Pharmaceutical Industries Limited
FY 2025
Product
84.6%$14.6B
Distribution Service
9.0%$1.6B
License
3.9%$678M
Product and Service, Other
2.5%$423M
CVSCVS Health Corporation
FY 2025
Pharmacy Revenue
58.9%$229.0B
Premiums
34.6%$134.8B
Front Store Revenue
5.5%$21.5B
Product and Service, Other
1.0%$3.9B

BHC vs PRGO vs PBH vs TEVA vs CVS — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLPBHLAGGINGCVS

Income & Cash Flow (Last 12 Months)

PBH leads this category, winning 3 of 6 comparable metrics.

CVS is the larger business by revenue, generating $407.9B annually — 369.5x PBH's $1.1B. PBH is the more profitable business, keeping 16.9% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, BHC holds the edge at +10.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricBHC logoBHCBausch Health Com…PRGO logoPRGOPerrigo Company p…PBH logoPBHPrestige Consumer…TEVA logoTEVATeva Pharmaceutic…CVS logoCVSCVS Health Corpor…
RevenueTrailing 12 months$10.6B$4.2B$1.1B$17.3B$407.9B
EBITDAEarnings before interest/tax$3.6B$58M$353M$3.3B$10.5B
Net IncomeAfter-tax profit-$1.2B-$1.8B$187M$1.6B$2.9B
Free Cash FlowCash after capex$990M$108M$267M$1.2B$7.4B
Gross MarginGross profit ÷ Revenue+61.7%+34.2%+56.4%+52.1%+13.9%
Operating MarginEBIT ÷ Revenue+22.9%-4.1%+29.2%+13.2%+1.5%
Net MarginNet income ÷ Revenue-11.3%-43.5%+16.9%+9.0%+0.7%
FCF MarginFCF ÷ Revenue+9.4%+2.6%+24.2%+6.8%+1.8%
Rev. Growth (YoY)Latest quarter vs prior year+10.5%-7.2%-2.4%+2.3%+6.2%
EPS Growth (YoY)Latest quarter vs prior year-22.7%-56.4%-20.5%+72.2%+63.1%
PBH leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

BHC leads this category, winning 4 of 6 comparable metrics.

At 12.7x trailing earnings, PBH trades at a 80% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, BHC's 6.4x EV/EBITDA is more attractive than TEVA's 17.6x.

MetricBHC logoBHCBausch Health Com…PRGO logoPRGOPerrigo Company p…PBH logoPBHPrestige Consumer…TEVA logoTEVATeva Pharmaceutic…CVS logoCVSCVS Health Corpor…
Market CapShares × price$2.1B$1.6B$2.6B$41.9B$111.4B
Enterprise ValueMkt cap + debt − cash$22.0B$5.1B$3.5B$55.8B$196.5B
Trailing P/EPrice ÷ TTM EPS13.31x-1.14x12.72x30.01x62.81x
Forward P/EPrice ÷ next-FY EPS est.1.32x5.56x12.02x14.55x12.19x
PEG RatioP/E ÷ EPS growth rate1.40x
EV / EBITDAEnterprise value multiple6.38x7.42x9.62x17.65x13.11x
Price / SalesMarket cap ÷ Revenue0.20x0.38x2.27x2.43x0.28x
Price / BookPrice ÷ Book value/share5.71x0.55x1.49x5.34x1.47x
Price / FCFMarket cap ÷ FCF2.13x11.12x10.62x36.52x14.27x
BHC leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

PBH leads this category, winning 7 of 9 comparable metrics.

BHC delivers a 5.9% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-51 for PRGO. PBH carries lower financial leverage with a 0.57x debt-to-equity ratio, signaling a more conservative balance sheet compared to BHC's 56.36x. On the Piotroski fundamental quality scale (0–9), PBH scores 8/9 vs PRGO's 4/9, reflecting strong financial health.

MetricBHC logoBHCBausch Health Com…PRGO logoPRGOPerrigo Company p…PBH logoPBHPrestige Consumer…TEVA logoTEVATeva Pharmaceutic…CVS logoCVSCVS Health Corpor…
ROE (TTM)Return on equity+5.9%-50.7%+10.2%+20.7%+3.9%
ROA (TTM)Return on assets-4.5%-19.8%+5.3%+3.9%+1.1%
ROICReturn on invested capital+8.2%+3.7%+9.1%+7.7%+5.0%
ROCEReturn on capital employed+10.6%+4.3%+10.4%+8.0%+6.1%
Piotroski ScoreFundamental quality 0–974885
Debt / EquityFinancial leverage56.36x1.35x0.57x2.20x1.24x
Net DebtTotal debt minus cash$19.9B$3.4B$946M$13.8B$85.1B
Cash & Equiv.Liquid assets$1.3B$532M$98M$3.6B$8.5B
Total DebtShort + long-term debt$21.2B$4.0B$1.0B$17.4B$93.6B
Interest CoverageEBIT ÷ Interest expense1.43x-7.20x7.40x2.51x2.11x
PBH leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TEVA leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in TEVA five years ago would be worth $34,625 today (with dividends reinvested), compared to $2,039 for BHC. Over the past 12 months, TEVA leads with a +104.6% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors TEVA at 58.4% vs PRGO's -25.2% — a key indicator of consistent wealth creation.

MetricBHC logoBHCBausch Health Com…PRGO logoPRGOPerrigo Company p…PBH logoPBHPrestige Consumer…TEVA logoTEVATeva Pharmaceutic…CVS logoCVSCVS Health Corpor…
YTD ReturnYear-to-date-20.6%-13.5%-10.8%+16.3%+10.6%
1-Year ReturnPast 12 months+21.8%-51.2%-32.9%+104.6%+34.7%
3-Year ReturnCumulative with dividends-4.4%-58.1%-8.3%+297.5%+36.6%
5-Year ReturnCumulative with dividends-79.6%-60.1%+18.4%+246.2%+17.0%
10-Year ReturnCumulative with dividends-79.6%-77.7%-3.7%-28.3%+3.5%
CAGR (3Y)Annualised 3-year return-1.5%-25.2%-2.8%+58.4%+11.0%
TEVA leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

CVS leads this category, winning 2 of 2 comparable metrics.

CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than PRGO's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricBHC logoBHCBausch Health Com…PRGO logoPRGOPerrigo Company p…PBH logoPBHPrestige Consumer…TEVA logoTEVATeva Pharmaceutic…CVS logoCVSCVS Health Corpor…
Beta (5Y)Sensitivity to S&P 5001.02x1.18x0.53x1.13x0.05x
52-Week HighHighest price in past year$8.69$28.44$89.37$37.35$88.63
52-Week LowLowest price in past year$4.41$9.23$51.24$14.99$58.35
% of 52W HighCurrent price vs 52-week peak+65.9%+41.2%+61.1%+96.4%+98.5%
RSI (14)Momentum oscillator 0–10052.360.936.473.569.3
Avg Volume (50D)Average daily shares traded1.8M3.4M478K6.6M7.4M
CVS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

PRGO leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: BHC as "Buy", PRGO as "Hold", PBH as "Buy", TEVA as "Buy", CVS as "Buy". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 8.3% for TEVA (target: $39). For income investors, PRGO offers the higher dividend yield at 9.81% vs CVS's 3.06%.

MetricBHC logoBHCBausch Health Com…PRGO logoPRGOPerrigo Company p…PBH logoPBHPrestige Consumer…TEVA logoTEVATeva Pharmaceutic…CVS logoCVSCVS Health Corpor…
Analyst RatingConsensus buy/hold/sellBuyHoldBuyBuyBuy
Price TargetConsensus 12-month target$8.00$20.00$66.00$39.00$95.20
# AnalystsCovering analysts3836174641
Dividend YieldAnnual dividend ÷ price+9.8%+3.1%
Dividend StreakConsecutive years of raises21010
Dividend / ShareAnnual DPS$1.15$2.67
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+2.0%0.0%0.0%
PRGO leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

PBH leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BHC leads in 1 (Valuation Metrics).

Best OverallPrestige Consumer Healthcar… (PBH)Leads 2 of 6 categories
Loading custom metrics...

BHC vs PRGO vs PBH vs TEVA vs CVS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is BHC or PRGO or PBH or TEVA or CVS a better buy right now?

For growth investors, Bausch Health Companies Inc.

(BHC) is the stronger pick with 8. 5% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Prestige Consumer Healthcare Inc. (PBH) offers the better valuation at 12. 7x trailing P/E (12. 0x forward), making it the more compelling value choice. Analysts rate Bausch Health Companies Inc. (BHC) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — BHC or PRGO or PBH or TEVA or CVS?

On trailing P/E, Prestige Consumer Healthcare Inc.

(PBH) is the cheapest at 12. 7x versus CVS Health Corporation at 62. 8x. On forward P/E, Bausch Health Companies Inc. is actually cheaper at 1. 3x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — BHC or PRGO or PBH or TEVA or CVS?

Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +246.

2%, compared to -79. 6% for Bausch Health Companies Inc. (BHC). Over 10 years, the gap is even starker: CVS returned +3. 5% versus BHC's -79. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — BHC or PRGO or PBH or TEVA or CVS?

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

05β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 2235% more volatile than CVS relative to the S&P 500. On balance sheet safety, Prestige Consumer Healthcare Inc. (PBH) carries a lower debt/equity ratio of 57% versus 56% for Bausch Health Companies Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — BHC or PRGO or PBH or TEVA or CVS?

By revenue growth (latest reported year), Bausch Health Companies Inc.

(BHC) is pulling ahead at 8. 5% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Bausch Health Companies Inc. grew EPS 430. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, BHC leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — BHC or PRGO or PBH or TEVA or CVS?

Prestige Consumer Healthcare Inc.

(PBH) is the more profitable company, earning 18. 9% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 18. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PBH leads at 29. 6% versus 2. 6% for CVS. At the gross margin level — before operating expenses — BHC leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is BHC or PRGO or PBH or TEVA or CVS more undervalued right now?

On forward earnings alone, Bausch Health Companies Inc.

(BHC) trades at 1. 3x forward P/E versus 14. 5x for Teva Pharmaceutical Industries Limited — 13. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

08

Which pays a better dividend — BHC or PRGO or PBH or TEVA or CVS?

In this comparison, PRGO (9.

8% yield), CVS (3. 1% yield) pay a dividend. BHC, PBH, TEVA do not pay a meaningful dividend and should not be held primarily for income.

09

Is BHC or PRGO or PBH or TEVA or CVS better for a retirement portfolio?

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 5%, TEVA: -28. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between BHC and PRGO and PBH and TEVA and CVS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BHC is a small-cap deep-value stock; PRGO is a small-cap income-oriented stock; PBH is a small-cap deep-value stock; TEVA is a mid-cap quality compounder stock; CVS is a mid-cap income-oriented stock. PRGO, CVS pay a dividend while BHC, PBH, TEVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

BHC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 37%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Stocks Like

PBH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 10%
Run This Screen
Stocks Like

TEVA

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

CVS

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 1.2%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform BHC and PRGO and PBH and TEVA and CVS on the metrics below

Revenue Growth>
%
(BHC: 10.5% · PRGO: -7.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.